Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Epidyolex in Infants and Toddlers With TSC, Dravet Syndrome, or Lennox-Gastaut Syndrome
2023-505851-33-00Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of cannabidiol in tuberous sclerosis complex (TSC), Dravet syndrome, Lennox-Gastaut syndrome (LGS) and 1 more, sponsored by GW Pharmaceuticals. Primary endpoints: Safety and tolerability of Epidyolex, Pharmacokinetics of cannabidiol and metabolites and 2 more. Started Nov 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)Dravet syndromeLennox-Gastaut syndrome (LGS)epilepsy
Beyond the preview
Go deeper on 2023-505851-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505851-33-00.